open access

Vol 24, No 1 (2017)
Original articles — Basic science and experimental cardiology
Submitted: 2016-06-27
Accepted: 2016-09-10
Published online: 2016-09-23
Get Citation

Association of factor XIII Val34Leu polymorphism and coronary artery disease: A meta-analysis

Jae Hyun Jung, Gwan Gyu Song, Jae-Hoon Kim, Young Ho Seo, Sung Jae Choi
DOI: 10.5603/CJ.a2016.0070
·
Pubmed: 27665853
·
Cardiol J 2017;24(1):74-84.

open access

Vol 24, No 1 (2017)
Original articles — Basic science and experimental cardiology
Submitted: 2016-06-27
Accepted: 2016-09-10
Published online: 2016-09-23

Abstract

Background: Factor XIII plays an important role in the stabilization of the linkage between fibrins and in the pathophysiology of coronary artery disease (CAD). The association between factor XIII Val34Leu polymorphism and CAD risk remains controversial.

Methods: We conducted a meta-analysis of 36 studies involving 26,940 cases and 34,694 controls. Subgroup analyses were performed with division of data into disease (myocardial infarction [MI], CAD without MI), age, and sex.

Results: Factor XIII Val34Leu polymorphism was significantly associated with ove all CAD risk (odds ratio [OR] = 1.09, 95% confidence interval [CI] = 1.03–1.06, p = 0.004) and MI risk (OR = 1.15, 95% CI 1.07–1.25, p = 0.0003), but not with CAD without MI risk (OR = 1.00, 95% CI 0.87–1.15, p = 0.96). In the subgroup analysis by age and sex, there was no association between Val34Leu polymorphism and CAD.

Conclusions: This meta-analysis found that factor XIII Val34Leu polymorphism was associated with CAD risk, especially MI, but not with CAD without MI. In addition, age and sex did not affect the relationship between factor XIII Val34Leu polymorphism and CAD risk.  

Abstract

Background: Factor XIII plays an important role in the stabilization of the linkage between fibrins and in the pathophysiology of coronary artery disease (CAD). The association between factor XIII Val34Leu polymorphism and CAD risk remains controversial.

Methods: We conducted a meta-analysis of 36 studies involving 26,940 cases and 34,694 controls. Subgroup analyses were performed with division of data into disease (myocardial infarction [MI], CAD without MI), age, and sex.

Results: Factor XIII Val34Leu polymorphism was significantly associated with ove all CAD risk (odds ratio [OR] = 1.09, 95% confidence interval [CI] = 1.03–1.06, p = 0.004) and MI risk (OR = 1.15, 95% CI 1.07–1.25, p = 0.0003), but not with CAD without MI risk (OR = 1.00, 95% CI 0.87–1.15, p = 0.96). In the subgroup analysis by age and sex, there was no association between Val34Leu polymorphism and CAD.

Conclusions: This meta-analysis found that factor XIII Val34Leu polymorphism was associated with CAD risk, especially MI, but not with CAD without MI. In addition, age and sex did not affect the relationship between factor XIII Val34Leu polymorphism and CAD risk.  

Get Citation

Keywords

factor XIII A Val34Leu, coagulation, coronary artery disease, myocardial infarction, meta-analysis

About this article
Title

Association of factor XIII Val34Leu polymorphism and coronary artery disease: A meta-analysis

Journal

Cardiology Journal

Issue

Vol 24, No 1 (2017)

Pages

74-84

Published online

2016-09-23

Page views

1562

Article views/downloads

1499

DOI

10.5603/CJ.a2016.0070

Pubmed

27665853

Bibliographic record

Cardiol J 2017;24(1):74-84.

Keywords

factor XIII A Val34Leu
coagulation
coronary artery disease
myocardial infarction
meta-analysis

Authors

Jae Hyun Jung
Gwan Gyu Song
Jae-Hoon Kim
Young Ho Seo
Sung Jae Choi

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl